In fact, the gene can be used to predict a worse prognosis for BM in ER- and PR-positive BC patients, which is the distinct finding of our study, as TOR1B expression is only observed in overall BC without subtype specificities (https://www.proteinatlas.org/ ENSG00000136816-TOR1B/immune + cell). Here, TOR1B is linked to breast cancer.